Innate Pharma S.A.
17, avenue de Luminy-BP 30191
13009 Marseille, France
January 11, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| | | | | |
| Attention: | Mr. Jimmy McNamara |
| | | | | |
| RE: | Innate Pharma S.A. |
| Registration Statement on Form F-3 (File No. 333-276164) |
| |
| Acceleration Request |
| Requested Date: January 15, 2024 |
| Requested Time: 4:30 p.m. Eastern Time |
Ladies and Gentlemen:
In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, Innate Pharma S.A. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on January 15, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable. The Registrant also hereby requests a copy of the written order verifying the effective date.
Please contact Linda Hesse of Jones Day at +33 1 56 59 39 39 if you have any questions concerning the foregoing. Thank you for your attention to this matter.
| | | | | |
| Very truly yours, |
|
| INNATE PHARMA S.A. |
| |
| |
| By: | /s/ Hervé Brailly |
| Hervé Brailly |
| Interim Chief Executive Officer |
| | | | | |
| cc: | Linda Hesse, Jones Day |
